Constipation is a common childhood complaint. In 90% to 95% of @entity1 , @entity1142 is functional, which means that there is no objective evidence of an underlying pathological condition. @entity968 ( @entity970 or @entity968 ) solution is an osmotic laxative agent that is absorbed in only trace amounts from the gastrointestinal tract and routinely used to treat chronic @entity1142 in adults. Here, we report the results of a meta-analysis of @entity970 -based laxatives compared with @entity11884 , milk of magnesia ( @entity14337 ), oral liquid @entity982 (mineral oil), or acacia fiber, @entity40715 fiber, and @entity948 in @entity1 . This meta-analysis was conducted in accordance with PRISMA guidelines and involved searches of MEDLINE, Cochrane, EMBASE, and Google Scholar databases up to February 10, 2014, using the keywords (Constipation OR Functional Constipation OR Fecal Impaction) AND ( @entity1 ) AND ( @entity968 OR Laxative). Primary efficacy outcomes included a number of stool passages/wk and percentage of @entity1 who reported satisfactory stool consistency. Secondary safety outcomes included @entity294 , @entity490 , @entity390 or @entity391 , @entity158 or straining at defecation, @entity11035 or flatulence, hard stool consistency, poor palatability, and @entity548 . We identified 231 articles, 27 of which were suitable for full-text review and 10 of which were used in the meta-analysis. @entity1 who were treated with @entity970 experienced more successful disimpaction compared with those treated with non- @entity970 laxatives. Treatment-related adverse events were acceptable and generally well tolerated. @entity970 -based laxatives are effective and safe for chronic @entity1142 and for resolving fecal impaction in @entity1 . @entity1 's acceptance of @entity970 -based laxatives appears to be better than non- @entity970 laxatives. Optimal dosages, routes of administration, and @entity970 regimens should be determined in future randomized controlled studies and meta-analyses.

Efficacy and complications of XXXX for treatment of @entity1142 in @entity1 : a meta-analysis.

@entity1 :: ('9606', 'Species') :: ['Children', 'Patients', 'children', 'patients'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity11884 :: ('MESH:D007792', 'Chemical') :: ['lactulose'] @entity548 :: ('MESH:D006470', 'Disease') :: ['rectal bleeding'] @entity40715 :: ('MESH:D011620', 'Chemical') :: ['psyllium'] @entity948 :: ('MESH:D005632', 'Chemical') :: ['fructose'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity11035 :: ('MESH:C535647', 'Disease') :: ['bloating'] @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin'] @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity14337 :: ('MESH:D008276', 'Chemical') :: ['magnesium hydroxide'] @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation'] @entity970 :: ('CHEBI:46793', 'Chemical') :: ['PEG'] @entity968 :: ('MESH:D011092', 'Chemical') :: ['Polyethylene Glycol', 'macrogol', 'Polyethylene glycol']
@entity968 :: (MESH:D011092,Chemical) :: ['polyethylene glycols']
